

**Socio-Demographic and Clinical Profiles of End-Stage Renal Disease Patients  
Undergoing Haemodialysis in Gaborone, Botswana**

Kebaabetswe Mosiko<sup>1</sup>, Godfrey M. Rwegerera<sup>2, 3\*</sup>, Debashis Basu<sup>1</sup>

<sup>1</sup>Department of Public Health Medicine, School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa

<sup>2</sup>Department of Internal Medicine, University of Botswana, Gaborone, Botswana

<sup>3</sup>Department of Medicine, Princess Marina Hospital, Gaborone, Botswana

**Corresponding author:**

Prof. Godfrey M. Rwegerera

University of Botswana

Private Bag 00713

Gaborone, Botswana

Email: grwege@yahoo.com

## **OPEN ACCESS JOURNAL**

### **Abstract**

#### **Background**

Chronic kidney disease has been on the rise worldwide as well as in sub-Saharan Africa. End-stage renal disease (ESRD) is a major public health problem worldwide and is associated with significant morbidity and mortality. There is a dearth of data on the epidemiology of ESRD patients on renal replacement therapy in sub-Saharan Africa including Botswana.

#### **Aim**

To describe the socio-demographic and clinical profiles of ESRD participants on haemodialysis by gender and HIV status in Botswana.

#### **Methods**

A cross sectional study involving participants undergoing maintenance haemodialysis in three centers was conducted between February and June 2019. Data was analysed using Stata 14 statistical software. Chi-square test, Fisher's exact test and t-test were used to determine association between socio-demographic/clinical characteristics and gender/HIV status.

#### **Results**

Overall, 107 participants were enrolled and 65.4% were males. Their mean age $\pm$  standard deviation at the time of initiation of haemodialysis was 47.5 $\pm$ 13.0 years. The prevalence of HIV-infection, diabetes mellitus and hypertension were 24.3%, 26.2% and 90.7%, respectively. The regular use of traditional medicine was ascertained in 43.9% of participants. HIV-infection was significantly associated with hypertension ( $p=0.04$ ) and low body mass index ( $p<0.01$ ). Reported use of traditional herbal medicine was a significant associated factor among males ( $p=0.01$ ). Unemployment rate among participants was 41.1%, with 54.5% of these participants attributing their unemployment to ill health, with women significantly more affected than men ( $p=0.04$ ).

#### **Conclusion**

Hypertension was the most common associated factor among our study participants. Participants on maintenance haemodialysis in our study were mostly males. Traditional herbal medicine use was significantly more common in men whereas female participants appeared to have higher prevalence of obesity compared to male counterparts. HIV-infected participants were significantly more likely to have low body mass index and be hypertensive. Women were significantly more likely to be unemployed due to ill health as compared to men. Prospective studies with large sample sizes are recommended to help understanding the role of individual associated factors in causing ESRD in Botswana and similar settings in sub-Saharan Africa.

**Keywords:** End stage renal disease, Haemodialysis, Gender, Human Immune Deficiency Virus, Botswana.

**Introduction**

Chronic kidney disease (CKD) has been on the rise worldwide as well as in sub-Saharan Africa (SSA) (1). The global prevalence of CKD was estimated to be 9.1% in 2017, an increase of 29.3% since 1990 (2). In SSA a systematic review and meta-analysis on the epidemiology of CKD found an overall prevalence of 13.9%. End-stage renal disease (ESRD), a common final pathway of CKD is a major public health problem worldwide and is associated with significant morbidity and mortality (3). The rise of the prevalence of ESRD expected over the next decades is driven by population aging, increasing prevalence of diabetes mellitus and hypertension (4, 5), poverty (6) and communicable diseases such as HIV and viral hepatitis which are more prevalent in Africa (7-9). The rise of ESRD is expected to be more marked in developing countries including SSA, as most of the communicable and non-communicable diseases are disproportionately on the rise (10). Botswana has one of the highest prevalence of HIV-infection in the world at 20.3%; this being the fourth highest only below South Africa, Lesotho and Eswatini (11). On the other hand, the majority of patients with HIV-infection are virologically suppressed (12) and live longer with increased risk of non-communicable diseases like diabetes and hypertension, which lead to CKD and ultimately ESRD. In Botswana, a study on patients admitted in adult medical ward of a tertiary hospital found a CKD prevalence of 16.3% and HIV-infection, hypertension and diabetes were significantly associated with CKD; with HIV-infection remaining significant in multivariate analysis (13). More than three quarters of those admitted with CKD already had ESRD (13).

Although data are increasingly being published characterizing the burden of CKD in SSA (1, 14), the profile of ESRD, has yet to be optimally described in most SSA settings including Botswana. On the other hand, nephrology services are not widely available and are mostly marred by severe shortage of human resources the SSA region. During the period when this study was conducted, Botswana had only three nephrologists who were all based in the capital city, Gaborone. In 2012, there were 34 patients on peritoneal dialysis at Princess Marina Hospital and a total of 21 on haemodialysis at private dialysis centres in Gaborone (15). In 2015, there were more than 300 patients being followed up at Princess Marina Hospital with a third of them on peritoneal dialysis, whereas the rest were on haemodialysis (16). All the patients were receiving haemodialysis services in private dialysis centers with the cost covered by Government of Botswana. Patients undergoing chronic haemodialysis

## **OPEN ACCESS JOURNAL**

provide a great opportunity for characterising ESRD in a manner that may provide a profile of the situation in Botswana. The purpose of this study was to describe the epidemiology of ESRD patients on chronic haemodialysis in Botswana by comparing their socio-demographic and clinical profiles based on gender and HIV status.

### **Methodology**

#### ***Study design and setting***

A cross sectional study was conducted from 1<sup>st</sup> February 2019 to 30<sup>th</sup> June 2019 among patients on maintenance haemodialysis in Gaborone, Botswana. We anticipated data collection to be completed within two months, however it took longer because data was collected by the first author who could only spare data collection time to weekend and off days as she had work/employment commitments. Participants for this study were enrolled from three private haemodialysis centers in Gaborone (South East), which is the capital city of Botswana. The haemodialysis centers are Renal Care Institute (RCI) which is located adjacent to Princess Marina Hospital, the main tertiary hospital in the country. Other haemodialysis units are based in the two private hospitals namely Gaborone Private Hospital and Bokamoso Private Hospital.

#### ***Study population***

The study population was obtained from the three haemodialysis centres mentioned above. It comprised of all ESRD patients on maintenance haemodialysis ( $\geq 3$  months). All the patients equal or above 21 years of age (consenting age in Botswana at the time the study was conducted) (17) who gave consent to participate were enrolled in the study.

#### ***Sample size***

Sample size for this study was obtained from a formula for cross-sectional design (18). We used hypertension, being one of the most common clinical characteristics among patients with ESRD on haemodialysis (19, 20) to compute our sample size. The minimum sample size of 94 participants was obtained using margin of error of 4% and prevalence of 95.9% of hypertension among haemodialysis participants in Germany (21) Sampling was not performed as we intended to approach and recruit all eligible participants who would consent to be enrolled in the study.

## **OPEN ACCESS JOURNAL**

### ***Data collection***

The demographic, clinical and laboratory data were extracted from medical records as well as through interviews by a structured case report form conducted by the first author. The following data were collected; -

#### ***Socio-demographic characteristics***

Age, gender, ethnicity (Black, White, Asian and Colored (22)). Level of education (none, primary, secondary, college/diploma, university/degree, postgraduate), and Employment status (employed, unemployed, unemployed due to ill health, retired).

#### ***History***

Medical history such as hypertension, diabetes mellitus, HIV status, hepatitis B and C and use of traditional herbal medicines. For participants who were HIV-infected, most recent CD4 count and viral load performed within three months of the period of data collection was recorded. Medical records (both paper and electronic) were reviewed together with self-reported history to verify the medical history.

#### ***Physical examination***

Anthropometric measurements [weight (kg), height (m) and body mass index (BMI) were calculated as follows; Weight (kg)/height (m) squared and categorised into underweight ( $<18.5\text{kg/m}^2$ ); normal weight ( $18.5 - 25\text{ kg/m}^2$ ); overweight ( $25 - 30\text{ kg/m}^2$ ); obesity ( $>30\text{ kg/m}^2$ ) according to WHO criteria (23). The anthropometric measurements are routinely performed for participants undergoing haemodialysis.

### ***Ethical considerations***

Ethical clearance to conduct the study was obtained from Faculty of Health Sciences Research Ethics Committee at the University of Pretoria as well as Ministry of Health (Republic of Botswana) and Life Healthcare Group (South Africa). Permission to conduct the study was also obtained from heads of respective haemodialysis centers. The principles of the Helsinki Declaration were taken into account and were upheld.

### ***Statistical analysis***


Socio-demographic and clinical characteristics were analysed using Stata14 software. For descriptive statistics, continuous data with normal distribution were analysed using mean

## **OPEN ACCESS JOURNAL**

and standard deviation (SD) whereas continuous data with non-normal distribution were analysed using median and interquartile range. Categorical data were analysed using percentages and males compared with females using  $\chi^2$  test and Fisher's exact statistics. Comparison between HIV-infected and HIV negative participants were conducted by independent t-test for continuous variables and  $\chi^2$  for binary variables respectively. A p-value below 0.05 was considered significant.

### **Results**

Overall, 175 participants were on maintenance haemodialysis and all of them met the eligibility criteria (21 years or older) at the time of data collection. Out of these, 44 participants declined consent, 13 were too sick to take part in the study and six (6) died before being enrolled. Five (5) of the eligible participants were on dialysis holidays; hence the final analysis involved 107 participants (figure 1) who were distributed as follows; Bokamoso Private Hospital (51), Renal Care Institute (42) and Gaborone Private Hospital (14).



**Figure 1. Flowchart of participants with ESRD on haemodialysis recruited in the study**

## **OPEN ACCESS JOURNAL**

### ***Socio-demographic profile of participants by gender***

Male gender comprised 65.4% (70/107) of all participants. Mean age of participants was 51.8 (SD 13.7 years), which was not statistically different across gender ( $p = 0.33$ ). More than half (52.3 %) of participants were in the age range 35 to 55 years when they started haemodialysis. The majority of the patients were black (97.2%) and literate having attended at least primary school education (92.5%). Unemployment rate among the study participants was 41.1% and among them over half (54.5%, 24/44) attributed their unemployment to ill health. The unemployment was significantly higher in females than in males (54.1% versus 34.3%) ( $P = 0.04$ ) (Table 1).

**Table 1: Distribution of demographic data of study participants by gender**

Parameters	Total (N=107)	Male (n=70)	Female (n=37)	P-value
<b>Age in years</b> (mean $\pm$ SD)	51.76 $\pm$ 13.67	52.91 $\pm$ 12.74	49.20 $\pm$ 15.09	0.33
<b>Ethnicity</b>				0.97
Black	104 (97.2 %)	68 (97.1%)	36 (97.3%)	
Asian	1 (0.9%)	1 (1.4%)	0 (0.0%)	
Colored	2 (1.9%)	1 (1.4%)	1 (2.7%)	
<b>Level of education</b>				0.03
None	8 (7.5%)	8 (11.4%)	0	
Literate**	99(92.5%)	62 (88.6%)	37 (100%)	
<b>Occupation</b>				0.04
Employed	41 (38.3%)	28 (40%)	13 (35.1%)	
Retired	22(20.6%)	18(25.7%)	4 (10.8%)	
Unemployed	44 (41.1%)	24 (34.3%)	20(54.1%)	

\*\*Literate refers to any sort of formal education whether completed or not

### ***Clinical profile of participants by gender***

Most participants (70.1%) had haemodialysis history spanning 2 to 10 years. Obesity was present in 11.2% of the participants. Prevalence of hypertension and diabetes mellitus was 90.7% (97/107) and 26.2% (28/107), respectively. Prevalence rates of HIV and Hepatitis B were 24.3% (26/107) and 5.6% (6/107), respectively, and no cases of hepatitis C were noted. The use of traditional herbal medicines before initiation of haemodialysis was reported by 43.9% (47/107) of participants with significantly higher prevalence in males ( $p = 0.01$ ) (table 2).

**OPEN ACCESS JOURNAL**

**Table 2: Clinical profiles of participants by gender**

Parameter	Total (N=107)	Males (n=70)	Females (n= 37)	p-value
Age at haemodialysis initiation (years)				
≤34	18 (16.8%)	10 (14.3%)	8 (21.6%)	0.28
35 – 55	56 (52.3%)	35 (50%)	21 (56.7%)	
≥ 56	33 (30.8%)	25 (35.7%)	8 (21.6%)	
Time in dialysis (years)				
0.5 – 2	27 (25.2%)	17 (24.3%)	10 (27.2%)	0.42
2.1 – 5	38 (35.5%)	24 (34.3%)	14 (37.8%)	
5.1 – 10	37 (34.6%)	24 (34.3%)	13 (35.1%)	
>10	5 (4.7%)	5 (7.14%)	0 (0%)	
Body mass index				
<25	69 (64.5%)	44 (62.8%)	25 (67.6%)	0.24
25.0 – 29.9	26 (24.3%)	20 (28.6%)	6 (16.2%)	
30 and above	12 (11.2%)	6 (8.6%)	6 (16.2%)	
History of hypertension	97 (90.7%)	64 (91.4%)	33 (89.2%)	0.71
History of diabetes mellitus	28 (26.2%)	21 (30%)	7 (18.9%)	0.21
HIV-infected	26 (24.3%)	15 (21.4%)	11 (29.7%)	0.34
Hepatitis B infection	6 (5.6%)	6 (8.6%)	0 (0%)	0.09
Traditional herbal medicine use	47 (43.9%)	37 (52.9%)	10 (27.0%)	0.01
CD4 count*(cells/ mm <sup>3</sup> ) median (IQR)	440 (310-565)	336 (242– 461)	538 (440 – 665)	0.48
Viral load* (copies) median (IQR)				
<400	19 (73.1%)	12 (80%)	7 (63.6%)	0.45
>400	1 (3.8%)	0 (0%)	1 (9.1%)	

\*Applicable only to HIV-infected participants

**Socio-demographic and clinical profiles of participants by HIV status**

Most of the studied socio-demographic and clinical profile variables including gender, ethnicity, employment status, education level and age at haemodialysis initiation were similar between HIV-infected and HIV-negative groups. The overall mean age  $\pm$  standard deviation at haemodialysis initiation was  $47.5 \pm 13.0$  years (not shown in Table 3). The mean age at haemodialysis initiation was similar between HIV-infected and HIV-negative participants ( $p=$



**OPEN ACCESS JOURNAL**

0.41) (Table 3). HIV-infected participants were significantly more likely to have either normal weight or be underweight as compared to HIV negative counterparts ( $p < 0.01$ ) (Table 3). On the other hand, HIV-infected participants had a significantly higher prevalence of hypertension as compared to HIV-negative counterparts ( $p=0.04$ ) (Table 3).

**Table 3: Socio-demographic and clinical profile of participants by HIV status**

Variables	HIV-infected N (%) = 26 (24.3%)	HIV-negative N (%) = 81 (75.7%)	p-value
<b>Ethnicity</b>			
Black	25 (96.2%)	79 (97.5%)	0.59
Asian	0 (0%)	1 (1.2%)	
Colored	1 (3.8%)	1 (1.2%)	
<b>Employment status</b>			
Employed	11 (42.3%)	29 (37.2%)	0.64
Retired	4 (15.4%)	18 (23.1%)	
Never employed	6 (23.1%)	14 (17.9%)	
Not working due to ill health	5 (19.2%)	17 (21.8%)	
<b>Level of education</b>			
None	3 (11.5%)	5 (6.3%)	0.37
Primary	3 (11.5%)	18 (22.5%)	
Secondary	11 (42.3%)	23 (28.8%)	
College/diploma	5 (19.2%)	13 (16.3%)	
University/degree	3 (11.5%)	16 (20.0%)	
Postgraduate	1 (3.8%)	6 (7.5%)	
<b>Body mass index (kg/m<sup>2</sup>)</b>			
<25	19 (73.1%)	50 (61.7%)	<0.01
25.0 – 29.9	6 (23.1%)	20 (24.7%)	
30 and above	1 (3.9%)	11 (13.6%)	
Mean age (SD) at dialysis initiation (years)	47±11.1	47.7±13.7	0.41
Mean number (SD) of years on dialysis (years)	4.1±3.8	3.8±2.9	0.68
History of hypertension	24 (92.3%)	71 (87.6%)	0.04
History of diabetes mellitus	3 (11.5%)	25 (30.9%)	0.05
Hepatitis B infection	1 (3.8%)	5 (6.2%)	0.10
Traditional herbal medicine use	12 (46.2%)	35 (43.2%)	0.79

## Discussion

This study provides information on socio-demographic and clinical profiles of participants on hemodialysis in Gaborone, the capital city of Botswana. Participants on hemodialysis in the studied centers are residing in Gaborone and surrounding towns and villages of South, East and parts of Central Botswana. Due to lack of local registry that describe demographics and clinic profile of participants in renal replacement therapy in Botswana, this study is of value as it adds to the knowledge base on ESRD patients and is of paramount importance in terms of providing baseline for future studies as well as estimating resources that can help improve the care of participants on renal replacement in Botswana.

Our study found that male gender and mean age of participants on haemodialysis was similar to those of other African studies (8, 9, 24). The male dominance of participants in our study has also been found in another study in Cameroon (25). This observation has also been reported worldwide and is explained by the fact that male gender is an independent risk for CKD (26, 27). On the other hand, the unemployment rate among participants in our study was higher than the overall unemployment rate in Botswana (28) probably due to their ill health; over half of the participants attributed their unemployment to ill health and the time lost due to dialysis sessions, which is similar in the United States of America (29) and Cameroon (25). The proportion of obesity among males and females were higher than the reported national prevalence of 3.2% and 8.4%, respectively (30) which is expected among patients with CKD (31, 32). Prevalence of diabetes mellitus was much higher than the general population in Botswana (30); and even among dialysis patients in other African countries (19, 33). The prevalence of hypertension was much higher than the general population in Botswana (9; and similar to haemodialysis patients in other countries such as Japan and Germany (20, 21). Several factors explain the higher prevalence of hypertension among patients with ESRD. They include; - increased frequency of sodium and water retention as renal function declines (34, 35) and endothelial dysfunction and arterial stiffness (37, 38). On the other hand, patients with ESRD demonstrate high levels of atrial natriuretic peptide (ANP) which is responsible for regulating salt and water balance in response to arterial wall stretch resulting to increased blood pressure levels (36, 37).

The prevalence of HIV-infection among our participants was understandably higher compared to the data from South African renal registry that documented HIV-infection prevalence of 12.7% among haemodialysis patients (38). The observed difference is most

**OPEN ACCESS JOURNAL**

likely a factor of sample size. The prevalence of hypertension was significantly higher among HIV-infected as compared HIV-negative participants. Our findings are similar to those of a worldwide systematic review and meta-analysis for estimation of the effects of antiretroviral therapy (ART) on blood pressure levels and hypertension risk among HIV-infected populations which demonstrated that exposure to ART was significantly associated with increased systolic and diastolic blood pressure levels, as well as increased risk of hypertension, regardless of study-level socio-demographic differences (39).

The relatively higher prevalence of hepatitis B in this study as compared to the previous study in Botswana (40) might be due to higher risk of nosocomial transmission and impaired host defence mechanisms (41) among haemodialysis patients. Our prevalence appears to be higher than those of another study of participants in haemodialysis in Botswana (42). The possible reasons for this discrepancy are time period difference for the two studies as well as differences in the sample sizes. Absence of Hepatitis C infection might be due to low yield of hepatitis C serology and low prevalence of hepatitis C in Botswana (43).

On the other hand, over 40% of study participants reported to have used traditional herbal medicine, which is similar to findings in South Africa (44). Male predominance of traditional herbal medicine use was similar to the findings of the study in South Africa (45). The major challenge in herbal medicine induced renal dysfunction is that reporting of herbal medicine use is voluntary and in most cases, patients often do not admit to using herbal medicines prior to haemodialysis initiation for fear of negative response from healthcare workers. This has resulted in paucity of data on herbal medicine nephrotoxicity (45).

**Limitations of the study**

The cross sectional study design employed cannot determine causal relationship, as the temporal sequence is not known. Secondly, reliance on limited and incomplete medical records made it difficult to determine factors associated with ESRD in our study. On the other hand, our eligibility criteria excluded participants below the age of 21 years. At the time of data collection, there was no participant below the age of 21 years on maintenance haemodialysis in our study sites. We are aware that several young participants were on peritoneal dialysis at the time this study was conducted. We have described the socio-demographic and clinical profiles of ESRD patients receiving maintenance haemodialysis but there are no data regarding patients with ESRD who defaulted dialysis and those who cannot be dialysed because of their geographical location. Hence, the findings of our study

## **OPEN ACCESS JOURNAL**

may not be generalizable among ESRD patients in Botswana. However, it should be noted that this is the first documented study in Botswana to describe the socio-demographic and clinical profiles of ESRD participants in haemodialysis; it provides a baseline for future large prospective studies that will cover the entire CKD population regardless of renal replacement therapy status.

### **Conclusion**

This multi-centre study adds critical information on socio-demographic and clinical profiles into of ESRD participants on haemodialysis in Botswana in the absence of renal registry data and representative population studies. Hypertension was the most common associated factor among our study participants. Participants on maintenance haemodialysis in our study were mostly males. Traditional herbal medicine use was significantly more common in men whereas female participants appeared to have higher prevalence of obesity compared to male counterparts. HIV-infected participants were significantly more likely to have low body mass index and be hypertensive. Women were significantly more likely to be unemployed due to ill health as compared to men. Prospective studies with large sample sizes are recommended to help understanding the role of individual associated factors in causing ESRD in Botswana and similar settings in sub-Saharan Africa.

### **Acknowledgements**

We acknowledge the cooperation of the staff at the haemodialysis centers.

### **Authors' contributions**

KM designed the study, conceptualized, collected data and drafted manuscript drafting. DB designed the study, supervised and critically revised the manuscript. GMR supervised and critically revised the manuscript. All the authors reviewed and approved the final version of the manuscript to be published.

### **Availability of data and materials**

The datasets generated during the current study are available from the corresponding author on reasonable request.

### **Competing interests:**

The authors declare that they have no competing interests.

**References**

1. Stanifer JW, Jing B, Tolan S, et al. **The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis.** Lancet Glob Health 2014; 2 (3): e174-e81.
2. GBD Chronic Kidney Disease Collaborators. **Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017.** Lancet 2020; 395 (10225): 709-33.
3. Grassmann A, Gioberge S, Moeller S, Brown G. **ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.** Nephrol Dial Transplant 2005; 20 (12): 2587-93.
4. Peer N, Kengne A-P, Motala AA, Mbanya JC. **Diabetes in the Africa region: 2013 update for the IDF diabetes Atlas 2013.**
5. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Vander Stichele R, Van Bortel LM. **Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies.** J Hypertens 2011; 29:1243-52.
6. Naicker S. **Burden of end-stage renal disease in sub-Saharan Africa.** Clin Nephrol 2010; 74 Suppl 1:S13-6.
7. Bamgboye EL. **End-stage renal disease in sub-Saharan Africa.** Ethn Dis 2005; 16(2 Suppl 2): S2-5-9.
8. Halle MP, Kengne AP, Ashuntantang G. **Referral of patients with kidney impairment for specialist care in a developing country of sub-Saharan Africa.** Ren Fail 2009; 31(5): 341-48.
9. Madala ND, Thusi GP, Assounga AG, Naicker S. **Characteristics of South African patients presenting with kidney disease in rural KwaZulu-Natal: a cross sectional study.** BMC Nephrol 2014; 15(1): 61.
10. Lozano R, Naghavi M, Foreman K, et al. **Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.** Lancet 2013; 380 (9859): 2095-2128.
11. World Health Organization. **HIV and AIDS in Botswana.**  
<https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/botswana>. Last accessed on 16th July 2021.

**OPEN ACCESS JOURNAL**

12. Gaolathe T, Wirth KE, Holme MP, et al. **Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.** Lancet HIV 2016; 3 (5): e221-230.
13. Rwegerera G, Bayani M, Taolo E, Habte D. **The prevalence of chronic kidney disease and associated factors among patients admitted at princess marina hospital, Gaborone, Botswana.** Niger J Clin Pract 2017; 20: 313-19.
14. Sumaili EK, Cohen EP, Zinga CV, Krzesinski JM, Pakasa NM, Nseka NM. **High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo.** BMC Nephrol 2009; 10:18.
15. **Kidney diseases deadly Gaborone: Government of Botswana;** 2012 [updated 2019; cited 2018 21/10/2018]. Available from: <http://www.gov.bw/en/News/Kidney-Diseases-deadly>. Last accessed on 10<sup>th</sup> November 2020.
16. **MOH intensifies search for sustainable kidney disease treatment.** Sunday Standard. 02/10/2015. <https://www.sundaystandard.info/moh-intensifies-search-for-sustainable-kidney-disease-treatment/>. Last accessed on 10<sup>th</sup> November 2020.
17. De Prettto-Lazarova A, Brancati-Badarau DO, Burri C. **Informed consent approaches for clinical trial participation of infants with minor parents in sub-Saharan Africa: A systematic review.** PloS One 2020; 15(8): e0237088.
18. Lemeshow S, Hosmer DW Jr, Klar J, Lwanga SK, editors. **Adequacy of sample size in health studies.** Chichester: John Wiley & Sons; 1990.
19. Elfaki AMH, Mohamed STA. **Prevalence of Hypertension and Diabetes Mellitus among Haemodialysis Patients at Elobied Haemodialysis Unit–West Sudan.** J Adv Med Res 2019:1-5.
20. Iseki K, Nakai S, Shinzato T, et al. **Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan.** Ther Apher Dial 2007; 11: 183. –8
21. **Hypertension, by DOPPS country and cross-section.**  
[https://www.dopps.org/annualreport/html/MCOMHTN\\_c\\_TAB2011.htm](https://www.dopps.org/annualreport/html/MCOMHTN_c_TAB2011.htm) . Last accessed on 17<sup>th</sup> July 2021
22. **Population & Housing Census 2011.**  
[https://www.statsbots.org.bw/sites/default/files/publications/national\\_statisticsreport.pdf](https://www.statsbots.org.bw/sites/default/files/publications/national_statisticsreport.pdf). Statistics Botswana. Last accessed on 15<sup>th</sup> November 2020

**OPEN ACCESS JOURNAL**

23. WHO. **Body mass index – BMI.** <https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi>. Last accessed on 07<sup>th</sup> November 2020.
24. Halle MP, Ashuntantang G, Kaze FF, Takongue C, Kengne AP. **Fatal outcomes among patients on maintenance haemodialysis in sub-Saharan Africa: a 10-year audit from the Douala General Hospital in Cameroon.** BMC Nephrol. 2016; 17(1):165.
25. Halle MP, Takongue C, Kengne AP, Kaze FF, Ngu KB. **Epidemiological profile of patients with end stage renal disease in a referral hospital in Cameroon.** BMC Nephrol 2015; 16 (1): 59.
26. Collins AJ, Foley RN, Herzog C, et al. **United States Renal Data System 2008 Annual Data Report.** Am J Kidney Dis 2009; 53 :S1–374
27. Goodkin DA, Young EW, Kurokawa K, Prütz K-G, Levin NW. **Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects.** Am J Kidney Dis 2004; 44 (Supplement 2(0)):16-21
28. Matandare M. **Botswana unemployment rate trends by gender: Relative analysis with upper middle income Southern African countries (2000-2016).** Dutch Journal of Finance and Management 2018; 2(2): 04.
29. Muehrer RJ, Schatell D, Witten B, Gangnon R, Becker BN, Hofmann RM. **Factors affecting employment at initiation of dialysis.** Clin J Am Soc Nephrol 2011; 6 (3):489-496.
30. **Botswana Demographic Survey 2017.**  
<https://www.statsbots.org.bw/sites/default/files/publications/Botswana%20Demographic%20Survey%20Report%202017.pdf>. Last accessed on 09<sup>th</sup> November 2020
31. Stenvinkel P, Carmine Zoccali C and Alp Ikizler T. **Obesity in CKD-What Should Nephrologists Know?** JASN 2013; 24 (11): 1727-36.
32. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. **End-stage renal disease in African-American and white men: 16-year MRFIT findings.** JAMA 1997; 277(16):1293-98.
33. Naicker S. **End-stage renal disease in Sub-Saharan Africa & 2013 International Society of Nephrology.** <https://www.kisupplements.com/action/showPdf?pii=S2157-1716%2815%2931135-7>. Last accessed on 25<sup>th</sup> July 2021
34. Sarafidis PA, Persu A, Agarwal R, et al. **Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-**



**OPEN ACCESS JOURNAL**

- m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *Nephrology Dialysis Transplantation* 2017; 32(4): 620-40
35. Bucharles SGE, Wallbach KK, Moraes TPd, Pecoits-Filho R. **Hypertension in patients on dialysis: diagnosis, mechanisms, and management.** *Brazilian Journal of Nephrology* 2018 (AHEAD): 0
  36. Fu S, Ping P, Wang F, Luo L. **Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.** *Journal of biological engineering* 2018; 12(1): 2
  37. Fishbane S, Natke E, Maesaka JK. **Role of volume overload in dialysis-refractory hypertension.** *American journal of kidney diseases* 1996; 28(2):257-61 (41)
  38. Davids MR, Jardine T, Marais N, Jacobs JC. **South African Renal Registry Annual Report 2016.** *Afr J Nephrol* 2018; 21(1): 61-72.
  39. Nduka C, Stranges S, Sarki A, Kimani P, Uthman O. **Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis.** *J Hum Hypertens* 2016; 30 (6):3
  40. Matthews PC, Beloukas A, Malik A, et al. **Prevalence and characteristics of hepatitis B Virus (HBV) co-infection among HIV-positive women in South Africa and Botswana.** *PLoS One* 2015; 10: e0134037.
  41. Wong PN, Fung TT, Mak SK, et al. **Hepatitis B virus infection in dialysis patients.** *J Gastroenterol Hepatol.* 2005; 20:1641-1651.
  42. Mahupe P, Molefe-Baikai OJ, Saleshando G, Rwegerera GM. **Prevalence and risk factors for Hepatitis B and C among End-stage renal disease patients on hemodialysis in Gaborone, Botswana.** *Niger J Clin Pract* 2021; 24(1): 81-88
  43. Patel P, Davis S, Tolle M, Mabikwa V, Anabwani G. **Prevalence of Hepatitis B and Hepatitis C Coinfections in an Adult HIV Centre Population in Gaborone, Botswana.** *Am J Trop Med Hyg* 2011; 85: 390-94.
  44. Peltzer K, Friend-du Preez N, Ramlagan S, Fomundam H. **Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa.** *BMC Public Health* 2008; 8 (1): 255.
  45. Jha V. **Herbal medicines and chronic kidney disease.** *Nephrol* 2010; 15:10-17.